Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zhongfeng Huiyu is a Traditional Chinese Medicine (TCM) formulation, typically administered as granules, developed by the Changchun University of Chinese Medicine for the treatment of ischemic stroke and post-stroke aphasia. The formula is designed to tonify qi, activate blood circulation, and resolve phlegm to open the orifices, which in a clinical context translates to improving cerebral microcirculation and supporting neuroregeneration. Clinical research conducted at the Affiliated Hospital of Changchun University of Chinese Medicine suggests that the treatment can significantly improve language function scores (such as the Western Aphasia Battery) and neurological deficit scores in patients recovering from acute or subacute ischemic stroke. Its therapeutic effects are associated with the modulation of neurotrophic factors and the reduction of inflammatory markers in the central nervous system.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on zhongfeng huiyu.